FAIR LAWN, N.J.--(BUSINESS WIRE)--Vyteris, Inc. (OTC BB: VYTR), manufacturer of the first FDA-approved active patch transdermal drug delivery system, in partnership with Ferring Pharmaceuticals, announced the completion of a Phase I dose ranging study using Vyteris’ patented Smart Patch transdermal system for delivery of a peptide hormone. The effective completion of this study is a key ingredient in the preparation work for Phase II studies.
